Search

everythinglearnresearchcommunity

for

Search:↓

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

A 3-year-old girl developed scurvy symptoms that improved with vitamin C but relapsed when supplementation stopped.

Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.

People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.

Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.

Alopecia areata was most common in people in their 30s and 40s, with some family history and a higher relapse rate, and larger bald areas responded better to specific immunotherapy.

COVID-19 increased alopecia areata relapses due to inflammation and stress.

Follicular unit extraction successfully restored hair growth in a leprosy patient without disease relapse.

Treatment with methotrexate and prednisolone led to complete hair regrowth and no relapse for 2 years.

Diphenylcyclopropenone (DPCP) can help regrow hair in many alopecia areata patients but may cause side effects and relapses.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Managing multiple autoimmune diseases in one patient is extremely challenging.

A possible link exists between minimal change nephrotic syndrome and complete hair loss.

A man wrongly believed he had parasites, showing that delusional infestation can affect men and is often linked with other psychiatric issues, but can be treated with antipsychotics.

New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.

A 60-year-old man with Cronkhite-Canada syndrome improved with treatment, but the condition has a high mortality rate and a risk of colorectal cancer.

Platelet-rich plasma treatment could potentially be an effective way to treat chronic alopecia areata with minimal side effects.

Injecting triamcinolone into the eyebrow area may help eyelash regrowth in alopecia areata patients.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.

Systemic retinoids may effectively treat erosive pustular dermatosis of the scalp.

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

Diphenylcyclopropenone (DPCP) is effective in treating alopecia areata, with most patients showing significant hair regrowth.

A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.

Managing severe infections in SLE patients requires tailored treatment strategies.